Developing and Costing Local Strategies to Improve Maternal and Child Health: The Investment Case Framework
article has not abstract
Vyšlo v časopise:
Developing and Costing Local Strategies to Improve Maternal and Child Health: The Investment Case Framework. PLoS Med 9(8): e32767. doi:10.1371/journal.pmed.1001282
Kategorie:
Health in Action
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1001282
Souhrn
article has not abstract
Zdroje
1. Boschi-PintoC, YoungM, BlackRE (2010) The child health epidemiology reference group reviews of the effectiveness of interventions to reduce maternal, neonatal and child mortality. Int J Epidemiol 2 39: i3–i6.
2. DarmstadtGL, BhuttaZA, CousensS, AdamT, WalkerN, et al. (2005) Evidence-based, cost-effective interventions: how many newborn babies can we save? Lancet 365: 977–988.
3. FryattR, MillsA, NordstromA (2010) Financing of health systems to achieve the health Millennium Development Goals in low-income countries. Lancet 375: 419–426.
4. Asia-Pacific MNCH health group (2008) An Investment Case for maternal, neonatal and child health in Asia and the Pacific.
5. KumarAKS, ChenLC, ChoudhuryM, GanjuS, MahajanV, et al. (2011) Financing health care for all: challenges and opportunities. Lancet 377: 668–679.
6. LakshminarayananR (2003) Decentralisation and its implications for reproductive health: the Philippines experience. Reprod Health Matters 11: 96–107.
7. MoHP (2010) National Health Sector Programme – Implementation Plan II (2010–2015). Kathmandu Ministry of Health and Population.
8. World Bank (2008) Investing in Indonesia's health: challenges and opportunities for future public spending. Jakarta: World Bank.
9. TomlinsonM, ChopraM, SandersD, BradshawD, HendricksM, et al. (2007) Setting priorities in child health research investments for South Africa. PLoS Med 4: e259 doi:10.1371/journal.pmed.1000259.
10. CampbellOM, GrahamWJ (2006) Strategies for reducing maternal mortality: getting on with what works. Lancet 368: 1284–1299.
11. RansonMK, HansonK, Oliveira-CruzV, MillsA (2003) Constraints to expanding access to health interventions: an empirical analysis and country typology. Journal of International Development 15: 15–39.
12. van Aken JE, Berends H, van der Bij H (2007) Problem solving in organisations - a methodological handbook for business students. Cambridge: Cambridge University Press.
13. TanahashiT (1978) Health service coverage and its evaluation. Bull World Health Organ 56: 295–303.
14. Soucat A, Van Lerberghe W, Diop F, Nam NS, Knippenberg R (2002) Marginal Budgeting for Bottlenecks: a new costing and resource allocation practice to buy health results. Using health sector's budget expansion to progress towards the Millennium Development Goals in Sub-Saharan Africa. Washington (D.C.): World Bank.
15. JonesG, SteketeeRW, BlackRE, BhuttaZA, MorrisSS (2003) How many child deaths can we prevent this year? Lancet 362: 65–71.
16. RudanI, KapiririL, TomlinsonM, BallietM, CohenB, et al. (2010) Evidence-based priority setting for health care and research: tools to support policy in maternal, neonatal, and child health in africa. PLoS Med 7: e1000308 doi:10.1371/journal.pmed.1000308.
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2012 Číslo 8
- Statiny indukovaná myopatie: Jak na diferenciální diagnostiku?
- MUDr. Dana Vondráčková: Hepatopatie sú pri liečbe metamizolom väčším strašiakom ako agranulocytóza
- Vztah mezi statiny a rizikem vzniku nádorových onemocnění − metaanalýza
- Nech brouka žít… Ať žije astma!
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
Najčítanejšie v tomto čísle
- Feasibility, Yield, and Cost of Active Tuberculosis Case Finding Linked to a Mobile HIV Service in Cape Town, South Africa: A Cross-sectional Study
- Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients
- Child Mortality Estimation: A Global Overview of Infant and Child Mortality Age Patterns in Light of New Empirical Data
- What Is the Optimal First Line Antiretroviral Therapy in Resource-Limited Settings?